Skip to main
BIIB
BIIB logo

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 42 analyst ratings
Buy
Strong Buy 36%
Buy 33%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

Biogen's stock outlook is bolstered by robust sales growth from its multiple sclerosis drug Vumerity, driven by favorable seasonal channel dynamics, along with strong expansion in international markets, particularly in China and Japan. The successful and accelerated launch of new products like Leqembi, Skyclarys, and Zurzuvae has exceeded consensus expectations, indicating effective commercial execution and a promising pipeline. Additionally, with a focus on cost savings from the "Fit for Growth" initiative and ongoing evaluation of business development opportunities, the company is well-positioned for sustained earnings growth into 2025, which further enhances its positive financial outlook.

Bears say

Biogen's management has indicated a projected mid-single digit decline in total revenue for 2025, primarily due to the anticipated market entry of Sandoz’s biosimilar of Tysabri in the U.S. and increased generic competition impacting Tecfidera sales. The company’s non-GAAP EPS for FY2025 is expected to fall between $15.25 and $16.25, reflecting foreign exchange headwinds and an overall decline in core pharmaceutical revenue as multiple sclerosis products are negatively affected. Although new product launches, including Leqembi and others, are set to contribute to revenue, they are not expected to sufficiently counterbalance the losses from the declining MS business.

Biogen (BIIB) has been analyzed by 42 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 33% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 42 analysts, Biogen (BIIB) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $252.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $252.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.